<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133210</url>
  </required_header>
  <id_info>
    <org_study_id>10-0533</org_study_id>
    <nct_id>NCT01133210</nct_id>
  </id_info>
  <brief_title>Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)</brief_title>
  <official_title>Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of maraviroc therapy in obese insulin
      resistant subjects on:

        1. Plasma triglyceride concentration

        2. Plasma HDL-cholesterol and LDL-cholesterol concentrations

        3. Plasma markers of cardiometabolic risk and inflammation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine, in obese insulin resistant subjects, the effect of
      maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on:

        1. Plasma triglyceride concentration

        2. Plasma HDL-cholesterol and LDL-cholesterol concentrations

        3. Plasma markers of cardiometabolic risk and inflammation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect of Maraviroc on plasma triglyceride concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will compare pre and post-treatment serum triglyceride concentrations in subjects receiving a 12 week course of either Maraviroc or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Maraviroc on serum HDL concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will compare pre and post-treatment serum HDL concentrations in subjects receiving a 12 week course of either Maraviroc or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of Maraviroc on serum LDL-cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will compare pre and post-treatment serum LDL-cholesterol concentrations in subjects receiving a 12 week course of either Maraviroc or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Maraviroc on plasma markers of cardiometabolic risk and inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will compare pre and post-treatment plasma concentrations of C-reactive protein and InterLeukin-6 in subjects receiving a 12 week course of either Maraviroc or placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 12 weeks of treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>dosage will be a 300mg Maraviroc pill twice a day for 12 weeks</description>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Selzentry</other_name>
    <other_name>Celsentri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obese (body mass index (BMI) between 30 and 45.9)

          -  increased plasma triglyceride concentrations (150-400 mg/dL)

        Exclusion Criteria:

          -  active or previous infection with hepatitis B or C

          -  history of alcohol abuse

          -  current alcohol consumption (&gt;20g/day)

          -  severe hypertriglyceridemia (&gt;400 mg/dL)

          -  active peptic ulcer disease

          -  diabetes

          -  pregnant or lactating

          -  take statins, fibrates, niacin, moderate to strong Cyp3A4 inhibitors or inducers, or
             any other medication that might confound interpretation of the study results will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>triglyceride</keyword>
  <keyword>cholesterol</keyword>
  <keyword>Maraviroc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

